The vertebrate genome contains a predicted 50 000±100 000 genes, many of unknown function. The recent development of morpholino-based gene knock-down technology in zebra®sh has opened the door to the genome-wide assignment of function based on sequence in a model vertebrate. This review describes technical aspects of morpholino use for functional genomics applications, including the potential for multigene targeting and known methodological limitations. The result of successful gene inactivation by this agent is proposed to yield embryos with a`morphant' phenotypic designation. The establishment of a morphant database opens the door to true functional genomics using the vertebrate, Danio rerio.
Introduction
The ability of the various genome projects to acquire gene sequence data has far outpaced our ability to ascribe biological functions to these new genes. How can we determine which of the increasing number of these uncharacterized gene products are involved in a given biological or disease process? This dilemma has led to the concept of a scienti®c ®eld called`functional genomics', which can be de®ned as the attempt to match biological function with gene sequence on a genome scale. For the many biological processes that are well conserved in evolution, model systems with rapid genetic tools, such as Drosophila melanogaster, have opened the door to functional genomics. In this paradigm, genes with speci®c biological roles are identi®ed ®rst in the model organism and genome databases are subsequently used to identify human homologues. The hedgehog and wnt signalling cascades are excellent examples of conserved pathways ®rst worked out in invertebrate model systems, with signi®cant implications on health and disease upon analysis of the human pathway equivalents.
Many biological and biochemical pathways are not conserved between worms,¯ies and vertebrates and, consequently, studies directly using biologically more complex model systems, such as the mouse and the ®sh, are warranted. Examples include neural crest formation, most organogenesis pathways, and signalling cascades such as that induced by vascular endothelial growth factor (VEGF). Indeed, studies with these more closely related model systems are required to understand many critical details of even conserved pathways and their implications on human health and disease. For example, the relationship between holoprosencephaly and hedgehog signalling was not clari®ed until work was performed in the ®sh, the mouse and in humans, despite the fundamental role of this pathway in the development of most animals on this planet [23] .
genes required for vertebrate-speci®c processes [4, 6] . Of the hundreds of developmental loci identi®ed, however, less than 50 have been molecularly characterized because of the dif®cult and timeconsuming nature of positional cloning and related methods [21] . Forward genetics in zebra®sh identi®es novel genes of interest but is limited by the laborious nature of the F3 genetic screens and the work required for molecular identi®cation of the mutant locus. Similar limitations apply to current chemical mutagenesis projects now under way in a variety of academic and commercial mouse laboratories.
Insertional mutagenesis methods using retroviruses are also currently used in zebra®sh genetics research [21] . This approach reduces the work required for the molecular assignment of function to sequence, but this tool is also signi®cantly lower in mutagenesis effectiveness compared to chemical agents. In addition, these screens currently require analyses of F3 embryos, requiring a signi®cant commitment to research infrastructure and animal facilities. The laboratory of Dr N. Hopkins is in the ®nal stages of a large insertional screen, and the expected outcome is the assignment of sequence to function of ca. 250±500 genes [1] . Other insertional mutagens based on transposons are under development [9, 17] . Transposons have the potential for performing F1 screens based on insertion site context (through gene or enhancer`trapping'), but their ef®cacy in a genome-wide screen is still unknown.
An alternative to ®sh or mouse forward genetic screens employs mouse ES cell technology in a reverse genetic approach. In this strategy, the sequence of an individual gene is altered or removed from the chromosome of murine ES cells and the gene's function directly determined, using speci®c developmental assays in mice carrying de®ciencies in both targeted chromosomes generated from these ES cells. This approach is limited by the signi®cant cost (i$100 000 per gene) and time (i1 year) required for the F3 mouse genetics work.
Morpholinos
An ideal gene targeting technique should be speci®c, straightforward to perform, competent for action in all cell types, ef®cient at depleting the selected protein, amenable to the targeting of many genes, have little or no non-speci®c effects, and be reproducible. RNA-based interference (RNAi) [10,22; for review, see 8] can often satisfy many of these requirements in the nematode and Drosophila. RNAi has been reported to work in zebra®sh, with highly variable and controversial results [11, 13, 24] , however. Other methods, including RNAse-Hmediated strategies, have been tried with only modest success [3] . This author wonders whether the effectiveness of RNAi to speci®cally remove gene function in mice [20, 25, 26] will be subject to the same potential ambiguities in targeting noted for zebra®sh [13] and Xenopus (Strege P, Ekker SC, unpublished observations).
Another strategy to inhibit gene function that has been recently shown to be extremely effective in zebra®sh embryos [12] employs the gene-targeting agents called morpholinos as sequence-speci®c translational inhibitors. Morpholinos are chemically modi®ed oligonucleotides with similar base stacking abilities as natural genetic material but have a morpholine moiety instead of a ribose [18, 19] . In addition, a phosphorodiamidate linkage is used, resulting in a neutral charge backbone. These two modi®cations form a modi®ed and highly soluble polymer capable of hybridizing single-stranded nucleic acid sequences with high af®nity and little cellular toxicity and are free of most or all non-speci®c side effects [18, 19] . Indeed, morpholinos are not subject to any known endogenous enzymatic degradation activity. Morpholinos have been shown to bind to and block translation of mRNA both in vitro and in tissue culture [18, 19] . In contrast to traditional antisense oligonucleotide approaches that utilize RNAse-Hbased degradation of mRNA as a mechanism of action, morpholinos appear to function through the hindrance of translational initiation [18, 19] . This alternative antisense approach makes morpholino targeting highly predictable for oligo design and signi®cantly reduces non-speci®c effects. Recent results in vivo have demonstrated the potential of this reagent for therapeutic and genomics applications [2, 7, 12, 16] . The use of morpholinos in zebra®sh have shown these compounds to be (a) sequence speci®c and (b) extremely potent in all cells during the ®rst 50 h of development in F0 zebra®sh embryos as targeted gene`knock-down' agents [12] . This time period in the zebra®sh embryo includes the fundamental vertebrate processes of segmentation and organogenesis. This tool offers the opportunity to pursue sequence speci®c gene targeting studies without the necessity of laborious, time-consuming and expensive F3 vertebrate genetic testing. Morpholinos thus offer a high throughput F0 vertebrate assay system for vertebrate functional genomics applications.
Known limitations of morpholino-based gene targeting
The major assumption to the use of morpholinos as gene-targeting agents is the success rate for speci®c gene inactivation. We generated morpholinos against known genes to determine an estimate of success rate. We have targeted shh, chordin, no tail, one-eyed-pinhead (oep), sparse, nacre, urod, bozozok/dharma, an EF1a±GFP transgene, pax 2.1, bmp1, bmp2b, bmp7, alk8, smad5, wnt5 and wnt11 (12; Nasevicius A, Ekker SC, unpublished observations; Hammerschmidt M, personal communication). With only one recent exception (pax 2.1), all genes targeted resulted in clear speci®c gene inactivation with the ®rst morpholino tried (16/17 or >94% success rate). This is an upper estimate of the expected rate against unknown genes. The effective rate will be reduced by morpholino mistargeting and any other non-speci®c effects. In some instances, a morpholino will also inhibit a second gene and result in embryos with a combined phenotype. An extreme example is represented by the bozozok/dharma morpholino, in which a second effect (CNS degeneration) is superimposed on the bozozok loss of function phenotype [12] . If these secondary, non-speci®c effects result in loss of embryonic structures or premature death of the embryo, then the function of the gene of choice will not be scorable using this technology. The reduction of morpholino success rate by this mistargeting rate (2/17) is thus a lower estimate of morpholino screening ef®ciency, yielding an initial morpholino screening rate of 82% (14/17) . A signi®cant fraction of these`missed' genes can be recovered by the use of a second morpholino of unrelated sequence. Assuming a similar speci®c success rate of ca. 80% for the remaining 18% of`missed' genes yields an additional 14% of genes potentially targeted by morpholinos, for a combined expected success rate of >95% for genes screened using two targeted morpholinos.
Potential explanations for some missed targets include a failure to inhibit the translation of genes with complex promoters ± transcripts with multiple leader sequences ± or to a failure to bind and inactivate a selected gene due to differences in genetic background. Should the leader sequence in a speci®c locus be especially prone to polymorphism, the selected gene might not be inactivated in all embryos due to the high speci®city of morpholino targeting in vivo. The one-eyed-pinhead locus is a potential example of this phenomenon [12] ; in one wild-type strain, only ca. 50% of embryos responded to this morpholino; in another, none. Other, less direct strain differences could also reduce the effectiveness of morpholinos. For example, variations in genetic backgrounds could alter the penetrance of a given morpholino effect due to genetic factors in a second, modulator locus. The characterization and inclusion of common`wildtype' and other non-isogenic laboratory strains in the sequencing project is suggested to make maximum use of morpholino technology in zebra®sh.
As with most genetic screens, morpholinos are also limited by functional redundancy, an issue especially relevant to vertebrates. Moreover, the zebra®sh genome contains an additional set of incomplete duplicates for an estimated 30% of genes found in mammals [14, 15] . This partial genome duplication occasionally results in two orthologues in zebra®sh for one in humans. One example is the sonic hedgehog locus [12] . Comparative expression pro®les of likely orthologues, however, demonstrate only a duplication of a subset of expression patterns for these genes. Indeed, no two orthologues have identical expression patterns in zebra®sh [5] . The use of morpholinos, however, is highly amenable to rapid tests of redundancy through the simultaneous targeting of genes of related sequence (see shh and twhh double knockdowns [12] ). Multigene targeting strategies are thus practical using current morphino technology, with an estimated minimum success rate of (0.82r0.82)=67%. For genes amenable to this strategy, morpholinos will be extremely effective at identifying and testing molecules with redundant functions in vivo.
Morphants
By analogy to the term`mutant', which describes animals in which a speci®c gene has been altered through mutation of the locus, we propose the term morphant' to describe animals in which a selected gene has been successfully inactivated by morpholino targeting. This simpli®cation retains the distinction between classical genetic approaches to loss of function and morpholino-based targeting strategies. In addition, the standard for describing à morphant' effect should be only after the results are con®rmed through either mRNA rescue or targeting using a second morpholino of unrelated sequence.
An example of the use of this term can be found in our compiled nascent morphant database (http:// beckmancenter.ahc.umn.edu/). Just as there is now a zebra®sh stock centre that carries many zebra®sh mutations, we now carry the sequence and aliquots of morpholinos that yield speci®c morphant effects for request by the zebra®sh community. A single, standard (300 nmol) morpholino synthesis generates suf®cient reagent for use by 50 or more labs interested in testing for a possible role of a particular gene in their selected biological process. This will be of value for genes with known mutations as well; analyses using morphant phenocopies can be an initial screening tool that does not require the care and maintenance of ®sh stocks that may or may not be of interest to that investigator. We will accept both sequence and reagent aliquots from labs interested in supporting this effort, and we plan to update and distribute the status of this database regularly with unpublished morphants, using the Zebra®sh Science Monitor. We will support this effort while there is expressed interest or until this database has been incorporated as a more formal part of the community infrastructure. In the future, the ability to screen a morphant database systematically for all genes involved in a particular biological process may move vertebrate functional genomics from the virtual to the real world. 
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